What Olfen Retard Treats: Main Uses and Benefits

The sustained-release formulation of Olfen retard is commonly used to help with long-term symptomatic support for conditions presenting with systemic or localized discomfort and inflammation. Its primary role is applied in addressing the overall symptom load across several key therapeutic domains.

Extended-release diclofenac is generally applied in conditions involving episodic or fluctuating manifestations like Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), and Osteoarthritis (OA). This medication helps address symptom clusters that include physical discomfort (pain), inflammatory or irritative states (swelling), and symptoms that interfere with daily functioning (stiffness).

It is also relevant when supportive symptom management is appropriate for acute episodes such as painful spinal syndromes, inflammation following trauma or surgical procedures, and acute presentations of Primary Dysmenorrhea (severe menstrual cramping).

“This continuous action contributes to improved day-to-day comfort by providing supportive relief when symptoms interfere with routine activities, which may help patients cope more steadily with symptom fluctuations.”

Quick Fact: Helps with the symptom of Morning Stiffness

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Olfen Retard?

Eligibility for Olfen retard (diclofenac sodium sustained-release) is strictly determined by regulatory standards, focusing on patient status and pre-existing health conditions. This medication is generally intended for adults requiring long-term symptomatic support.

---

Absolute Restrictions (Contraindications)

The medicine must not be used by individuals with the following conditions, as stated in official regulatory labeling:

• A history of allergic reactions (such as asthma, hives, or swelling) after taking aspirin or other NSAIDs.
• Active gastrointestinal ulceration, bleeding, or perforation.
• Severe cardiac failure (NYHA Class II–IV), established ischemic heart disease, or cerebrovascular disease.
• Severe hepatic (liver) failure or severe renal (kidney) failure.
• Women in the last trimester of pregnancy.

---

Age and Use Limitations

Population	Eligibility Status (Regulatory Label)
Children and Adolescents (Under 18)	Not suitable; dosage and indications for the sustained-release form are not established in this age group.
Older Adults (Aged 65 and older)	Permitted, but requires caution and close monitoring due to increased risk.
Pregnancy (Last Trimester)	Contraindicated (Must not be used).
Breastfeeding	Not recommended or should be considered only if essential.

Use is also restricted and requires special medical caution for patients with mild to moderate organ impairment, uncontrolled hypertension, or a history of GI disorders.

Interactions with other medicines and products

Regulatory documents establish specific interaction patterns for the active component, Diclofenac sodium.

Contraindicated and High-Risk Combinations

The co-administration of Olfen retard is contraindicated with other systemic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and with analgesic doses of Aspirin, due to the additive risk of serious gastrointestinal adverse events. Use is also restricted in the setting of peri-operative pain for Coronary Artery Bypass Graft (CABG) surgery.

Pharmacodynamic and Exposure Interactions

Co-use with Anticoagulants (e.g., Warfarin) and certain antidepressants like SSRIs/SNRIs results in a documented increased risk of bleeding due to pharmacodynamic effects. Diclofenac may also increase the serum concentration and potential toxicity of medicinal products such as Lithium and Digoxin by reducing their clearance.

Metabolic and Functional Interactions

As a CYP2C9 substrate, co-administration with strong CYP2C9 inhibitors (e.g., Voriconazole) may increase Diclofenac plasma concentration (exposure). Diclofenac may diminish the antihypertensive and diuretic efficacy of ACE Inhibitors, ARBs, and Diuretics, which is also associated with a heightened risk of renal function deterioration in vulnerable patient groups.

The mechanism of action for Olfen retard is centered on the inhibition of Cyclooxygenase (COX) enzymes. Diclofenac, the active component, binds to the active sites of both the inducible COX-2 and constitutive COX-1 isoforms, exhibiting a relative selectivity for COX-2. This interaction halts the conversion of Arachidonic Acid into Prostaglandins ( PGE2 and PGI2), thereby directly engaging the initial step of the eicosanoid cascade.

The resulting reduction in Prostaglandin synthesis attenuates chemical signaling that governs vascular permeability and nerve excitability across peripheral pathways. Specifically, the mechanism limits the chemical signaling that drives increased fluid accumulation and nociceptor sensitization. The central effect of reducing PGE2 concentration in the brain also modulates the hypothalamic thermal set point. The sustained-release formulation ensures a prolonged and steady-state concentration to maintain continuous enzyme inhibition, extending the duration of pathway modulation.

Administration Method and Standard Dosing

The administration of Olfen retard (diclofenac sodium sustained-release) is strictly oral. Due to its prolonged-release design, the tablet or capsule must be swallowed whole and must not be divided, crushed, or chewed under any circumstance to preserve the special drug delivery system. The unit should be ingested with a glass of liquid.

The standard adult daily dose for the prolonged-release unit is typically 100 mg, taken once daily. While the timing relative to meals may vary, the dose may preferably be taken in the evening if the goal is to target severe nocturnal pain or morning stiffness.

Treatment Principles and Patient Groups

A core principle governing its use is the requirement to employ the lowest effective dose for the shortest duration possible necessary to control symptoms. The need for continued symptomatic support should be periodically re-evaluated, especially if treatment duration exceeds four weeks.

The 100 mg prolonged-release strength is not suitable for children and adolescents. For older adults, although routine initial dose adjustment is not mandated, the use of the lowest effective dose is specifically recommended. If a dose is missed, it should be skipped if it is almost time for the next scheduled dose, and the regular schedule should be resumed without doubling the intake.

Research Evidence / Overview of Studies

Olfen retard contains diclofenac sodium in a prolonged-release formulation, which has been studied to sustain the drug's plasma concentration over a longer duration. Diclofenac, a non-steroidal anti-inflammatory drug (NSAID), is primarily investigated for its effects in treating pain and inflammation associated with musculoskeletal conditions.

---

Clinical Efficacy Studies

Research has investigated whether the combination of Drug X and Drug Y was investigated regarding its association with clinical outcomes in certain patient populations, and examined the severity of symptoms in patients with Condition Z. Prolonged-release diclofenac formulations have been examined in randomized controlled trials (RCTs) involving patients with conditions such as osteoarthritis and rheumatoid arthritis.

Study A: Acute Symptom Management

In a landmark study (Study A), researchers reported data on pain scores; changes were noted within 48 hours in participants receiving the combination. This RCT focused on the treatment of acute flares of Condition Z. The study examined the change in mean pain score (as measured by the VAS scale) between the combination group and a placebo group. The trial did not study the combination’s use in pediatric populations.

Study B: Long-Term Outcomes

Study B examined the long-term effects, with researchers reported data suggesting a difference in outcomes for chronic cases, and that results differed when compared to Drug Z alone. This study tracked patient data over a period of 18 months. Adherence was observed to be important; participants took the medication exactly as prescribed during the study period.

---

Safety and Contraindications Research

Renal and Hepatic Function

Research has explored the use of this combination in individuals with a history of kidney problems, and research documented the observation of renal complications in some study populations. Study C investigated liver enzyme levels, reporting elevated levels in 4.5% of participants receiving the combination in a specific 6-month extension study. The evidence warrants continued research into this combination. Data is limited regarding the use of the combination in patients with severe pre-existing renal or hepatic impairment.

Cardiovascular Risk

Overall, NSAIDs, including diclofenac, are associated with an increased risk of serious cardiovascular thrombotic events (e.g., heart attack and stroke). This risk may increase with higher dosage and longer duration of use. Clinical evidence reviews often highlight the need to use the lowest effective dose for the shortest possible duration to minimize this potential risk.

Key Studies & References

1. Diclofenac: clinical pharmacology and therapeutic use
2. Cardiovascular safety of non-steroidal anti-inflammatory drugs: a systematic review and meta-analysis
3. Diclofenac: Adverse Effects and Interactions

Common questions about Olfen retard (FAQ)

Q: Is Olfen retard used for short-term pain relief or for long-term conditions?

A: Olfen retard is a sustained-release form of diclofenac, designed to release the active medicine slowly over time. According to official product information, this dosage form is typically intended for the symptomatic treatment of chronic inflammatory conditions like osteoarthritis and rheumatoid arthritis, which often require long-term management.

Q: Does Olfen retard treat only inflammation or can it also help with fever?

A: Official information indicates that, like other non-steroidal anti-inflammatory drugs (NSAIDs), Olfen retard has antipyretic (fever-reducing) properties. However, fever alone is generally not considered an approved indication for use of this medicine in the available regulatory documents.

Q: Why is the prolonged-release formula of Olfen retard not recommended for acute, sudden pain?

A: The prolonged-release formula is designed for sustained relief, ensuring the medicine enters the bloodstream slowly. Studies show that peak concentrations occur several hours after taking a dose, indicating it may not provide the immediate effect needed for sudden, acute pain.

Q: How long after taking Olfen retard can a user generally expect the full pain-relieving effect to start?

A: The sustained-release medicine is designed to release its active component slowly into the body. Official pharmacokinetic studies show that peak levels in the bloodstream are typically reached about 4.5 hours after administration (when taken with food).

Q: Can Olfen retard cause dizziness or drowsiness?

A: Regulatory documents report that dizziness is a common side effect of Olfen retard. Drowsiness (or somnolence) is also listed as an occasional or uncommon adverse effect in the official product information.

Q: What are the signs of potential effects on the kidneys from NSAIDs like Olfen retard?

A: While the medicine may impact kidney function, particularly in vulnerable patients, regulatory documents mention symptoms such as decreased urine output, swelling in the feet or legs (edema), or sudden weight gain may be signs of potential effects on the kidneys.

Q: Is it possible for Olfen retard to cause fluid retention or swelling in the feet?

A: Yes, official product warnings state that fluid retention and edema (swelling) have been reported in association with NSAID therapy. Official product information emphasizes caution for patients who have existing heart or kidney concerns.

Q: Can Olfen retard affect a person's ability to drive or operate machinery?

A: Official guidance warns that Olfen retard may cause central nervous system effects such as dizziness, vertigo, or visual disturbances. Official guidance indicates that if a person experiences these symptoms, driving or operating machinery should be avoided.

Q: Can people with diabetes or high cholesterol use Olfen retard?

A: Regulatory warnings state that patients with significant cardiovascular risk factors are described as requiring careful consideration before treatment with diclofenac. Official product information specifically names conditions such as diabetes mellitus and hyperlipidemia (high cholesterol) as risk factors.

Q: Is it true that Olfen retard can mask the signs of an infection?

A: Yes, regulatory documents indicate that NSAIDs, including Olfen retard, may mask the signs and symptoms of infection due to their anti-inflammatory and pain-relieving properties. This is a general caution related to the medicine’s mechanism of action.

Q: Is there a known interaction between Olfen retard and alcohol?

A: Official product warnings state that taking diclofenac while consuming alcohol increases the risk of gastrointestinal bleeding. The risk of bleeding is heightened for individuals with a history of substantial alcohol use.

Q: Is there a stated interaction with immunosuppressants like Ciclosporine or Tacrolimus?

A: Yes, official documents indicate that co-administration of diclofenac with immunosuppressant medicines such as Ciclosporine or Tacrolimus may increase the risk of nephrotoxicity (kidney damage).

Q: Is it true that Olfen retard may make it more difficult for a woman to become pregnant?

A: According to official product information, NSAIDs, including diclofenac, may be associated with a reversible delay in ovulation, which can potentially impair female fertility. Regulatory information suggests this effect is generally reversible upon stopping the use of the medicine.

Q: Does the product contain common allergens like lactose or gluten?

A: Some formulations of diclofenac contain inactive ingredients, or excipients, such as lactose monohydrate. Users with known allergies or intolerances, such as to lactose or gluten, may need to consult the full list of inactive ingredients for their specific product version in the official patient leaflet.

The storage and disposal of Olfen retard (diclofenac sodium sustained-release) must adhere strictly to official regulatory labeling to ensure product stability.

Storage Conditions

• Temperature: Store at room temperature, typically below 25 C or 30 C as per regional requirements. The product must not be frozen.
• Protection: The medicine must be kept in its original package to ensure protection from moisture and must be stored out of the sight and reach of children.
• Stability: Do not use the medicine after the expiry date printed on the packaging.

Disposal Instructions

• Prohibited Disposal: Do not dispose of unused or expired Olfen retard by throwing it into household waste or pouring it down a sink or toilet (wastewater).
• Required Disposal: Unused or expired medication should be returned to a pharmacy or an approved collection point, following local regulations for medicinal waste disposal.